ArticleClinical drug investigation2025

Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States.

Ibrahim Alfayoumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.